Medicare Part D Payment Demonstration Under Consideration At CMS
Executive Summary
CMS Acting Administrator notes the agency has been discussing approaches to a Part D payment experiment with manufacturers interested in ‘defining’ such a program.
You may also be interested in...
Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.
Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.
Value-Based Contracting Needs Federal Safe Harbors To Flourish, Lilly Says
Lilly USA Deputy General Counsel Weems and former Anthem Chief Medical Officer Nussbaum offer insights on how guidance from the HHS Inspector General might help advance value-based contracting.